Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer

BACKGROUND: Androgen-deprivation therapy is well-established for treating prostate cancer but is associated with bone loss and an increased risk of fracture. We investigated the effects of denosumab, a fully human monoclonal antibody against receptor activator of nuclear factor-κB ligand, on bone mi...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Smith, Matthew R., Egerdie, Blair, Toriz, Narciso Hernández, Feldman, Robert, Tammela, Teuvo L.J., Saad, Fred, Heracek, Jiri, Szwedowski, Maciej, Ke, Chunlei, Kupic, Amy, Leder, Benjamin Z., Goessl, Carsten
Médium: Artigo
Jazyk:Inglês
Vydáno: 2009
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3038121/
https://ncbi.nlm.nih.gov/pubmed/19671656
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa0809003
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky